Zhao Jun, Yue Tian, Lu Shibi, Meng Haoye, Lin Qiuxia, Ma Haiyang, Liu Guangbo, Li Huo, Lu Qiang, Wang Aiyuan, Xu Wenjing, Feng Jing, Wan Yiqun, Liao Sida, Zhou Xuefeng, Peng Jiang
Medical School of Chinese PLA, Beijing, 100853, China.
Institute of Orthopedics, Chinese PLA General Hospital, Beijing Key Laboratory (No BZ0128), Beijing Key Lab of Regenerative Medicine in Orthopedics, Key Laboratory of Musculoskeletal Trauma & War Injuries PLA, Beijing, 100853, China.
J Orthop Translat. 2021 Mar 8;27:132-138. doi: 10.1016/j.jot.2020.08.005. eCollection 2021 Mar.
Osteonecrosis of the femoral head (ONFH) is a refractory disease due to its unclear pathomechanism. Neither conservative treatment nor surgical treatment during the early stage of ONFH achieves satisfactory results. Therefore, this study aims to explore the available evidence on the effect of zoledronic acid on early-stage ONFH.
For groups were established:the Normal group, model group, Normal saline group(NS group) and zoledronic acid-treated group The blood supply to the femoral head of animals in the model group and zoledronic acid-treated group was interrupted via a surgical procedure, and zoledronic acid was then locally administered to the femoral head. Four weeks after surgery, all the hips were harvested and evaluated by micro-CT and histopathology(H&E staining, TRAP staining, Toluidine blue staining and masson staining).
The values of BMD, BS/BV and Tb.Th in the Normal group and zoledronic acid-treated group were significantly higher than those in the model group and NS group (p < 0.05). The outcome of H&E staining, Toluidine blue staining and masson staining were consistent with that of micro-CT.
The local administration of zoledronic acid in the femoral head had positive effects on the bone structure of the femoral head in a modified rat model of traumatic ONFH and offered a promising therapeutic strategy during the early stage of ONFH.
This article could provide a choice for treating patients who have osteonecrosis of femora head and can be the basic research for advanced development over this disease.
由于发病机制不明，股骨头坏死（ONFH）是一种难治性疾病。在ONFH早期，保守治疗和手术治疗均未取得满意效果。因此，本研究旨在探讨唑来膦酸对早期ONFH疗效的现有证据。
设立四组：正常组、模型组、生理盐水组（NS组）和唑来膦酸治疗组。通过手术阻断模型组和唑来膦酸治疗组动物股骨头的血液供应，然后将唑来膦酸局部注入股骨头。术后四周，采集所有髋关节，通过显微CT和组织病理学（苏木精-伊红染色、抗酒石酸酸性磷酸酶染色、甲苯胺蓝染色和马松染色）进行评估。
正常组和唑来膦酸治疗组的骨密度、骨表面积/骨体积比和骨小梁厚度值显著高于模型组和NS组（p<0.05）。苏木精-伊红染色、甲苯胺蓝染色和马松染色的结果与显微CT结果一致。
在创伤性ONFH改良大鼠模型中，股骨头局部注射唑来膦酸对股骨头骨结构有积极影响，为ONFH早期治疗提供了一种有前景的治疗策略。
本文可为股骨头坏死患者的治疗提供一种选择，并可为该疾病的进一步研究提供基础。
